HEALTH UTILITY SCORES ACROSS MAJOR CANCER TYPES BY STAGE AND TREATMENT PHASE
Author(s)
Jade Xiao, PhD1, Zizi Elsisi, PhD1, Andrew ElHabr, PhD1, Christopher Tyson, PhD2, Xiting Cao, PhD2, A Mark Fendrick, MD3, Paul Limburg, MD2, Tomasz M. Beer, MD, FACP2, Ashish A. Deshmukh, PhD4, Jag Chhatwal, PhD5;
1Value Analytics Labs, Boston, MA, USA, 2Exact Sciences Corporation, Madison, WI, USA, 3School of Public Health, University of Michigan, Ann Arbor, MI, USA, 4Medical University of South Carolina, Charleston, SC, USA, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
1Value Analytics Labs, Boston, MA, USA, 2Exact Sciences Corporation, Madison, WI, USA, 3School of Public Health, University of Michigan, Ann Arbor, MI, USA, 4Medical University of South Carolina, Charleston, SC, USA, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
OBJECTIVES: Health-related quality-of-life (HRQoL) is a key component of cost-effectiveness analysis, but patient-reported QoL measures among cancer patients and survivors can be highly heterogeneous. We aimed to summarize health utility scores (HUS) for 14 solid tumor cancer types by stage and treatment phase.
METHODS: We conducted a review of published literature reporting EQ-5D-based HUS among cancer patients and survivors. The following rubric was used to assess the quality of estimates (“>” translates to “preferred over”): (1) Systematic reviews > Cohort studies > Clinical trials > Modeling studies; (2) U.S. > Other countries; (3) Urban settings > Rural settings; (4) Larger sample sizes > Smaller sample sizes; (5) EQ-5D-5L > EQ-5D-3L; (6) Mean > Median. Treatment phase was classified as “initial” (patients newly diagnosed, currently receiving or recently ended treatment) or “continuing” (patients >1 year after diagnosis or treatment).
RESULTS: HUS were obtained from 20 studies. Seven cancer types (cervical, colorectal, endometrial, esophageal, gastric, lung, pancreatic) had complete stratification by stage and phase. For the other seven cancer types, there was no or partial stratification by stage and/or treatment phase. Data missingness was resolved on a case-by-case basis by substituting missing values with the most suitable available values. Overall, esophageal, gastric, and pancreatic cancer had the lowest HUS; endometrial and prostate cancer had the highest HUS. Initial phase HUS ranged from 0.69 (esophageal) to 0.91 (endometrial) for stage I, 0.73 (pancreatic) to 0.91 (endometrial) for stage II, 0.70 (gastric) to 0.89 (prostate) for stage III, and 0.60 (colorectal) to 0.83 (endometrial) for stage IV. Continuing phase HUS ranged from 0.73 (pancreatic) to 0.92 (endometrial) for stages I-III, and 0.66 (esophageal) to 0.92 (endometrial) for stage IV.
CONCLUSIONS: There was large variation in data quality due to heterogeneous study types. HUS reporting would benefit from improved standardization of study populations and data collection approaches.
METHODS: We conducted a review of published literature reporting EQ-5D-based HUS among cancer patients and survivors. The following rubric was used to assess the quality of estimates (“>” translates to “preferred over”): (1) Systematic reviews > Cohort studies > Clinical trials > Modeling studies; (2) U.S. > Other countries; (3) Urban settings > Rural settings; (4) Larger sample sizes > Smaller sample sizes; (5) EQ-5D-5L > EQ-5D-3L; (6) Mean > Median. Treatment phase was classified as “initial” (patients newly diagnosed, currently receiving or recently ended treatment) or “continuing” (patients >1 year after diagnosis or treatment).
RESULTS: HUS were obtained from 20 studies. Seven cancer types (cervical, colorectal, endometrial, esophageal, gastric, lung, pancreatic) had complete stratification by stage and phase. For the other seven cancer types, there was no or partial stratification by stage and/or treatment phase. Data missingness was resolved on a case-by-case basis by substituting missing values with the most suitable available values. Overall, esophageal, gastric, and pancreatic cancer had the lowest HUS; endometrial and prostate cancer had the highest HUS. Initial phase HUS ranged from 0.69 (esophageal) to 0.91 (endometrial) for stage I, 0.73 (pancreatic) to 0.91 (endometrial) for stage II, 0.70 (gastric) to 0.89 (prostate) for stage III, and 0.60 (colorectal) to 0.83 (endometrial) for stage IV. Continuing phase HUS ranged from 0.73 (pancreatic) to 0.92 (endometrial) for stages I-III, and 0.66 (esophageal) to 0.92 (endometrial) for stage IV.
CONCLUSIONS: There was large variation in data quality due to heterogeneous study types. HUS reporting would benefit from improved standardization of study populations and data collection approaches.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR16
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities
Disease
SDC: Oncology